May 30, 2019

A roundtable discussion with Drs Neelima Denduluri, Shom Goel, Erika Hamilton, Komal Jhaveri, Ruth M O’Regan and Sara M Tolaney featuring review of patterns of care survey results, presentation of relevant data sets and moderated panel discussion.

• Module 1: Biology of the CDK4/6 Pathway and Pharmacology of the CDK4/6 Inhibitors Abemaciclib, Ribociclib and Palbociclib
  • General medical oncologist survey results (0:00)
  • Presentation of relevant data sets — Dr Goel (2:27)
  • Panel discussion (11:02)
• Module 2: Management of ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) in Postmenopausal Patients
  • General medical oncologist survey results (17:17)
  • Presentation of relevant data sets — Dr Denduluri (18:54)
  • Panel discussion (21:53)
• Module 3: Role of CDK4/6 Inhibitors for Premenopausal Patients with ER-Positive, HER2-Negative mBC
  • General medical oncologist survey results (30:38)
  • Presentation of relevant data sets — Dr Jhaveri (31:31)
  • Panel discussion (41:59)
• Module 4: Site and Extent of Metastases, Including CNS Involvement, and Outcomes with CDK4/6 Inhibitors; Predictors of Response to Therapy
  • General medical oncologist survey results (1:5:57)
  • Presentation of relevant data sets — Dr Tolaney (1:7:28)
  • Panel discussion (1:19:33)
• Module 5: Pathophysiology of Class- and Agent-Specific Toxicities and Optimal Management Strategies
  • General medical oncologist survey results (1:37:04)
  • Presentation of relevant data sets — Dr Hamilton (1:38:12)
  • Panel discussion (1:52:15)
• Module 6: Mechanisms of Resistance to CDK4/6 Inhibitors, Treatment Beyond Disease Progression and Novel Strategies with Combinations
  • General medical oncologist survey results (2:00:03)
  • Presentation of relevant data sets — Dr O’Regan (2:01:39)
  • Panel discussion (2:06:26)

Select publications